@BramDL

Biochemical engineer, PhD medical science @karolinskainst and @ugent, #ProstateCancer, #LiquidBiopsy & @ProBioTrial researcher. Views are my own

 Ghent, Belgium
crig.ugent.be/en/dr-bram-de-laere-phd
Joined November 2016
  • Tweets346
  • Following642
  • Followers363
31Media
Privileged seeing the @ProBioTrial published in @NatureMedicine My sincerest gratitude for all the dedicated doctors, nurses, lab personnel, trial managers, and most importantly, the patients who made this possible🙏 Thank you @komop_tgkanker for making ProBio possible in🇧🇪
ProBio@ProBioTrial20 Aug 2024
🔥📢 The first results from the @ProBioTrial have been published in @NatureMedicine 🚀🌟 ARPIs outperform taxanes in metastatic #ProstateCancer: an outcome-adaptive randomized platform trial 🌟 nature.com/articles/s41591-0… [1/10]

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive...

Nature Medicine - In a biomarker-driven, outcome-adaptive platform trial for patients with metastatic castration-resistant prostate cancer, androgen receptor pathway inhibitors showed longer...

nature.com
4
5
1
23
1,878
Bram De Laere retweeted
Piet Ost@piet_ostSep 7
Replying to @piet_ost @ProBioTrial
Accrual is fast, now with Finland and Denmark added, it will go even faster! If pharma is interested, @ProBioTrial is looking for new molecules to be tested!
2
8
344
Bram De Laere retweeted
Piet Ost@piet_ostSep 7
What is next in @ProBioTrial? Do we need ADT as a backbone in mHSPC?
2
7
12
991
Bram De Laere retweeted
Piet Ost@piet_ostSep 7
What did @ProBioTrial prove in mCRPC? What can you do with the info of a liquid biopsy? From a concept starting in 2019 to practice informing data from PFS, OS and QoL (out soon) data.
2
4
2
27
3,158
Bram De Laere retweeted
ProBio@ProBioTrialMay 20
💡However, comparative randomised evidence is available from the ProBio trial (NCT03903835) in men with ARPI-naïve mCRPC and detectable ctDNA. Compared to taxanes, ARPIs were associated with: ✅ Longer time of clinical benefit (PCWG3) ✅ Longer overall survival ✅ Fewer (S)AE
1
3
4
270
Bram De Laere retweeted
ProBio@ProBioTrialMay 20
📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.
🤖 Made with AI
2
3
6
528
Bram De Laere retweeted
Michael Saerens@msaerens01Mar 30
The workflow of #ProBio trial is mindblowing: 14 day TAT to get a ctDNA 🩸🧬genomic profile and personalised treatment option in >5 🇪🇺 countries. Focus shifts to mHSPC setting. @crighent Priomic Symposium @piet_ost @BramDL
3
4
391
🚨 Our latest study in @ESMO_Open unveils key genomic alterations that could predict treatment response and outcome in #bladdercancer #MIBC patients receiving neoadjuvant chemotherapy (NAC) before cystectomy. 🧬🧪 #precisiononcology 👉sciencedirect.com/science/ar… 1/5
1
2
102
more replies
📉 CDKN1A mutations weren’t tied to NAC response but were linked to worse survival outcomes — hinting at prognostic value regardless of molecular subtype. #Biomarkers 4/5
1
58
These findings could refine #PersonalizedMedicine and patient stratification in perioperative MIBC management and inform trials of FGFR inhibitors or alternative therapies. 🔍🎯🧬 👉check out the full study in @ESMO_Open: sciencedirect.com/science/ar… 5/5
1
53
Bram De Laere retweeted
Edmond Kwan@EdmondMKwan27 May 2025
On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP study, now published in @NatureMedicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across Australia 🙏🏼 🧵1/10 nature.com/articles/s41591-0…
13
41
2
102
8,728
Bram De Laere retweeted
Piet Ost@piet_ost17 May 2025
Replying to @medoncodoc @DrSpratticus
But if you ask the companies @Merck to provide drug for a biomarker selection trial like @ProBioTrial, they refuse. Even if you ask for compassionate use for PCa MSI high in the trial!!! @BramDL
1
2
4
409
Bram De Laere retweeted
Piet Ost@piet_ost5 May 2025
📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity
18
103
7
215
22,342
Proud to share the latest insights from the @ProBioTrial Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant #ProstateCancer 🩸🧬 Full text available on @EurUrolOncol : authors.elsevier.com/sd/arti…
ProBio@ProBioTrial22 Apr 2025
🚨 New Study Alert! 🚨 What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC A thread 🧵👇 #CancerResearch #ProstateCancer [1/8]
1
4
202
Bram De Laere retweeted
ProBio@ProBioTrial22 Apr 2025
🏅Secondary result: We found a linear relationship between ctDNA 🩸 levels and outcome: 📉 Every 10% increase in ctDNA fraction led to a 9% decrease in the observed survival time. 💡 The more ctDNA in🩸, the worse the outcome! #PrecisionMedicine [5/8]
1
4
7
319
Bram De Laere retweeted
ProBio@ProBioTrial22 Apr 2025
🏅Key result: 🧬🩸 Compared to those with detectable ctDNA, men with undetectable ctDNA had ➡️a 60% longer time before treatment stopped working (time to no longer clinically benefiting, NLCB) ➡️a 51% longer overall survival (OS) 📉 #CancerBiomarkers [4/8]
1
1
2
79
Bram De Laere retweeted
ProBio@ProBioTrial22 Apr 2025
🚨 New Study Alert! 🚨 What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC A thread 🧵👇 #CancerResearch #ProstateCancer [1/8]
2
6
1
9
666
Important work from the ProBio team! Proud to be a contributor. #probio #prostatecancer @BramDL @piet_ost @ReneeBultijnck eur03.safelinks.protection.o…
1
4
101
Bram De Laere retweeted
UroToday.com
@urotoday21 Nov 2024
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j @ProBioTrial
9
14
1,507
Load more